Development and implementation of a novel metric score (SciMet) for scientific publications.
Uložené v:
| Názov: | Development and implementation of a novel metric score (SciMet) for scientific publications. |
|---|---|
| Autori: | Sánchez-Díaz E; Department of Gynecology, Clínica Las Américas AUNA Instituto de Cancerología, Medellín, Colombia., Viveros-Carreño D; Unidad Ginecología Oncológica, Grupo de Investigación GIGA, Centro de Tratamiento e Investigación Sobre Cáncer Luis Carlos Sarmiento Angulo - CTIC, Bogotá, Colombia.; Department of Gynecologic Oncology, Clínica Universitaria Colombia, Bogotá, Colombia., Levin G; Division of Gynecologic Oncology, McGill University, Montreal, QC, Canada.; Department of Gynecologic Oncology, Hadassah Medical Center, Faculty of Medicine, Hebrew University, Jerusalem, Israel., Ramírez PT; Department of Obstetrics and Gynecology, Neal Cancer Center, Houston Methodist Hospital, Houston, USA., Pareja R; Department of Gynecologic Oncology, Instituto Nacional de Cancerología, Bogotá, Colombia.; Department of Gynecologic Oncology, Clínica ASTORGA, Medellín, Colombia. |
| Zdroj: | International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics [Int J Gynaecol Obstet] 2025 Sep; Vol. 170 (3), pp. 1024-1032. Date of Electronic Publication: 2025 Apr 11. |
| Spôsob vydávania: | Journal Article; Systematic Review |
| Jazyk: | English |
| Informácie o časopise: | Publisher: Wiley Country of Publication: United States NLM ID: 0210174 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-3479 (Electronic) Linking ISSN: 00207292 NLM ISO Abbreviation: Int J Gynaecol Obstet Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2017- : Malden, MA : Wiley Original Publication: [New York, NY] Hoeber Medical Division, Harper & Row, [c1969- |
| Výrazy zo slovníka MeSH: | Journal Impact Factor* , Gynecology* , Bibliometrics* , Medical Oncology* , Periodicals as Topic*/standards , Periodicals as Topic*/statistics & numerical data, Humans ; Female ; Genital Neoplasms, Female/therapy |
| Abstrakt: | There is no formal or standard measure of quality, clinical impact, and scientific merit in the current literature in gynecologic oncology besides formal citation metrics. We aimed to develop and implement a multiparametric score to identify influential articles with transformative impact in gynecology oncology. We conducted a systematic search using PubMed from January 2010 to December 2022 for gynecologic oncology publications. Publications were ranked based on citations per year, top 100 were selected. After excluding 17, 83 original articles were included. A multiparametric score (SciMet) was developed to assess its relevance and impact considering citations per year, journal impact factor, study design, sample size, and altmetric attention score; numeric scores were assigned based on quartiles. This scoring system was applied to articles with citations per year values above the median (39 articles). Thirty-nine studies were analyzed based on the score. Number of CPY ranged from 42.7 to 261.2; journal IF, from 17.76 to 202.7; and sample size from 20 to 1 672 983. The total SciMet score ranged from 17 to 47 (median of 34). The top 10 included studies addressed screening interventions for ovarian cancer, PARP inhibitors and bevacizumab use as first-line maintenance in ovarian cancer, surgical trials in cervical cancer, and HPV vaccination impact on cervical intraepithelial neoplasia or cancer development. Articles with higher scores were mostly randomized clinical trials, and besides having high metrics, led to changes in management of gynecologic cancers, resulting in their incorporation into guidelines that shape established norms in the field. (© 2025 International Federation of Gynecology and Obstetrics.) |
| References: | Dursun P, Gultekin M, Ayhan A. World gynecologic oncology publications and the Turkish contribution to the literature between 2000 and 2007. Asian Pac J Cancer Prev. 2011;12(4):861‐864. Loscalzo J. The future of medical journal publishing: the journal Editor's perspective: looking Back, looking forward. Circulation. 2016;133(16):1621‐1624. Pavlik EJ, Hoff J, Woolum D, et al. Metrics of the gynecologic oncology literature focused on cited utilization and costs. Gynecol Oncol. 2014;132(2):423‐427. Ioannidis JPA. Why Most clinical research is not useful. PLoS Med. 2016;13(6):e1002049. Pritchard A. Statistical bibliography or bibliometrics. J Doc. 1969;25:348. Franchignoni F, Özçakar L, Negrini S. Basic bibliometrics for dummies and others: an overview of some journal‐level indicators in physical and rehabilitation medicine. Eur J Phys Rehabil Med. 2018;54(5):792‐796. https://www.minervamedica.it/index2.php?show=R33Y2018N05A0792. Duan Y, Zhang P, Zhang T, Zhou L, Yin R. Characterization of global research trends and prospects on platinum‐resistant ovarian cancer: a bibliometric analysis. Front Oncol. 2023;13:1151871. Zheng W, Wu Y, Wang Y, Cheng J, Shen W. Bibliometric and visualized analysis of the top‐100 highly cited articles on immunotherapy for endometrial cancer. Medicine (Baltimore). 2023;102(27):e34228. Levin G, Brezinov Y, Meyer R, Oranim N. Gynecologic oncology top‐cited articles: an international analysis. Minerva Obstet Gynecol. 2023;76(2):188‐193. Bohl MA, Ponce FA. Assessing the relevancy of highly cited works in neurosurgery. Part I: the 100 Most relevant papers in neurosurgical journals. World Neurosurg. 2017;104:927‐938. Ramos MB, Koterba E, Rosi Júnior J, Teixeira MJ, Figueiredo EG. A bibliometric analysis of the Most cited articles in neurocritical care research. Neurocrit Care. 2019;31(2):365‐372. Moon JY, Yun EJ, Yoon DY, et al. Analysis of the altmetric top 100 articles with the highest altmetric attention scores in medical imaging journals. Jpn J Radiol. 2020;38(7):630‐635. Mitra AN, Aurora N, Grover S, Ananth CV, Brandt JS. A bibliometric analysis of obstetrics and gynecology articles with highest relative citation ratios, 1980 to 2019. Am J Obstet Gynecol MFM. 2021;3(1):100293. Garfield E. Short history of citation classics commentaries [Internet]. Citation Classics. [cited 2024 Apr 9]. https://garfield.library.upenn.edu/classics.html. Oaknin A, Tinker AV, Gilbert L, et al. Clinical activity and safety of the anti–programmed death 1 monoclonal antibody Dostarlimab for patients with recurrent or advanced mismatch repair–deficient endometrial cancer: a nonrandomized phase 1 clinical trial. JAMA Oncol. 2020;6(11):1766. Moore K, Colombo N, Scambia G, et al. Maintenance Olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495‐2505. Hamanishi J, Mandai M, Ikeda T, et al. Safety and antitumor activity of anti–PD‐1 antibody, nivolumab, in patients with platinum‐resistant ovarian cancer. J Clin Oncol. 2015;33(34):4015‐4022. Ronco G, Dillner J, Elfström KM, et al. Efficacy of HPV‐based screening for prevention of invasive cervical cancer: follow‐up of four European randomised controlled trials. Lancet. 2014;383(9916):524‐532. Matulonis UA, Shapira‐Frommer R, Santin AD, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE‐100 study. Ann Oncol. 2019;30(7):1080‐1087. Falcaro M, Castañon A, Ndlela B, et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register‐based observational study. Lancet. 2021;398(10316):2084‐2092. Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP‐ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof‐of‐concept trial. Lancet. 2010;376(9737):245‐251. doi:10.1016/S0140-6736(10)60893-8. González‐Martín A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391‐2402. Ramirez PT, Frumovitz M, Pareja R, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer. N Engl J Med. 2018;379(20):1895‐1904. Joura EA, Giuliano AR, Iversen OE, et al. A 9‐valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711‐723. Burger RA, Fleming GF, Mannel RS, Greer BE, Liang SX. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473‐2483. doi:10.1056/NEJMoa1104390. Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet. 2017;390(10106):1949‐1961. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484‐2496. Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum‐sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154‐2164. Coleman RL, Fleming GF, Brady MF, et al. Veliparib with first‐line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med. 2019;381(25):2403‐2415. Ray‐Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first‐line maintenance in ovarian cancer. N Engl J Med. 2019;381(25):2416‐2428. Menon U, Gentry‐Maharaj A, Burnell M, et al. Ovarian cancer population screening and mortality after long‐term follow‐up in the UK collaborative trial of ovarian cancer screening (UKCTOCS): a randomised controlled trial. Lancet. 2021;397(10290):2182‐2193. doi:10.1016/S0140-6736(21)00731-5. Lei J, Ploner A, Elfström KM, et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020;383(14):1340‐1348. Liu B, Liu S, Alastra AJ, et al. The 100 Most cited vs. Most relevant articles in the journal of neurosurgery: a bibliometric analysis. Cureus. 2019;11(4):e4498. Grover S, Elwood AD, Patel JM, Ananth CV, Brandt JS. Altmetric and bibliometric analysis of obstetrics and gynecology research: influence of public engagement on citation potential. Am J Obstet Gynecol. 2022;227(2):300.e1‐300.e44. The New England Journal of Medicine. About NEJM [Internet]. About NEJM. [cited 2024 Feb 6]. https://www.nejm.org/about‐nejm/about‐nejm. Hirsch JE. An index to quantify an individual's scientific research output. Proc Natl Acad Sci. 2005;102(46):16569‐16572. Ahangar H, Siamian H, Yaminfirooz M. Evaluation of the scientific outputs of researchers with similar H index: a critical approach. Acta Inform Med. 2014;22(4):255‐258. doi:10.5455/aim.2014.22.255-258. Wang J, Alotaibi NM, Ibrahim GM, Kulkarni AV, Lozano AM. The Spectrum of Altmetrics in neurosurgery: the top 100 “trending” articles in neurosurgical journals. World Neurosurg. 2017;103:883‐895.e1. Haustein S, Peters I, Sugimoto CR, Thelwall M, Larivière V. Tweeting biomedicine: an analysis of tweets and citations in the biomedical literature. J Assoc Inf Sci Technol. 2014;65(4):656‐669. Robinson‐García N, Torres‐Salinas D, Zahedi Z, Costas R. New data, new possibilities: exploring the insides of altmetric.Com. El Prof Inf. 2014;23(4):359‐366. Levin G, Harrison R, Meyer R, Ramirez PT. Impact of podcasting on novel and conventional measures of academic impact. Int J Gynecol Cancer. 2023;33(2):183‐189. Armstrong DK, Alvarez RD, Bakkum‐Gamez JN, et al. Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(2):191‐226. Koh WJ, Abu‐Rustum NR, Bean S, et al. Cervical cancer, version 3.2019. JNCCN J Natl Compr Canc Netw. 2019;17(1):64‐84. doi:10.6004/jnccn.2019.0001. Colombo N, Sessa C, Du Bois A, et al. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol. 2019;30(5):672‐705. Hirte H, Yao X, Ferguson SE, May T, Elit L. An Ontario health (Cancer Care Ontario) clinical practice guideline: consolidation or maintenance systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma. Curr Oncol. 2021;28(2):1114‐1124. Tew WP, Lacchetti C, Ellis A, et al. PARP inhibitors in the Management of Ovarian Cancer: ASCO guideline. J Clin Oncol. 2020;38(30):3468‐3493. Pothuri B, Alvarez Secord A, Armstrong DK, et al. Anti‐cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID‐19 pandemic crisis. Gynecol Oncol. 2020;158(1):16‐24. Chang HK, Shim SH, Lee M, et al. Informed consent forms for gynecologic cancer surgery: recommendations from the Korean Society of Gynecologic Oncology. Obstet Gynecol Sci. 2022;65(2):105‐112. Disis ML, Adams SF, Bajpai J, et al. Society for Immunotherapy of cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer. J Immunother Cancer. 2023;11(6):e006624. Hirte H, Poon R, Yao X, et al. Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II–IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: a practice guideline. Curr Oncol. 2022;29(1):231‐242. Gonzalez‐Martín A, Bover I, Del Campo JM, Redondo A, Vidal L. SEOM guideline in ovarian cancer 2014. Clin Transl Oncol. 2014;16(12):1067‐1071. doi:10.1007/s12094-014-1229-z. Dyer M, Richardson J, Robertson J, Adam J. NICE guidance on bevacizumab in combination with paclitaxel and carboplatin for the first‐line treatment of advanced ovarian cancer. Lancet Oncol. 2013;14(8):689‐690. Min KJ, Kwon SH, Kim K, et al. Clinical guideline for 9‐valent HPV vaccine: Korean Society of Gynecologic Oncology Guideline. J Gynecol Oncol. 2019;30(2):e31. The Society of Gynaecologic Oncology. SGO member update:Emerging data on the surgical approach for radical hysterectomy in the treatment of women with cervical cancer [Internet]. [cited 2024 Feb 6]. https://www.sgo.org/clinical‐practice/guidelines/sgo‐member‐update‐emerging‐data‐on‐the‐surgical‐approach‐for‐radical‐hysterectomy‐in‐the‐treatment‐of‐women‐with‐cervical‐cancer/. O'Malley DM, Krivak TC, Kabil N, Munley J, Moore KN. PARP inhibitors in ovarian cancer: a review. Target Oncol. 2023;18(4):471‐503. Habibzadeh F, Habibzadeh P, Yadollahie M. On determining the most appropriate test cut‐off value: the case of tests with continuous results. Biochem Med. 2016;26(3):297‐307. doi:10.11613/BM.2016.034. |
| Contributed Indexing: | Keywords: bibliometrics; female; genital neoplasms; manuscript; medical; ovarian neoplasms; uterine cervical neoplasms |
| Entry Date(s): | Date Created: 20250411 Date Completed: 20250823 Latest Revision: 20250911 |
| Update Code: | 20250911 |
| DOI: | 10.1002/ijgo.70147 |
| PMID: | 40214934 |
| Databáza: | MEDLINE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | There is no formal or standard measure of quality, clinical impact, and scientific merit in the current literature in gynecologic oncology besides formal citation metrics. We aimed to develop and implement a multiparametric score to identify influential articles with transformative impact in gynecology oncology. We conducted a systematic search using PubMed from January 2010 to December 2022 for gynecologic oncology publications. Publications were ranked based on citations per year, top 100 were selected. After excluding 17, 83 original articles were included. A multiparametric score (SciMet) was developed to assess its relevance and impact considering citations per year, journal impact factor, study design, sample size, and altmetric attention score; numeric scores were assigned based on quartiles. This scoring system was applied to articles with citations per year values above the median (39 articles). Thirty-nine studies were analyzed based on the score. Number of CPY ranged from 42.7 to 261.2; journal IF, from 17.76 to 202.7; and sample size from 20 to 1 672 983. The total SciMet score ranged from 17 to 47 (median of 34). The top 10 included studies addressed screening interventions for ovarian cancer, PARP inhibitors and bevacizumab use as first-line maintenance in ovarian cancer, surgical trials in cervical cancer, and HPV vaccination impact on cervical intraepithelial neoplasia or cancer development. Articles with higher scores were mostly randomized clinical trials, and besides having high metrics, led to changes in management of gynecologic cancers, resulting in their incorporation into guidelines that shape established norms in the field.<br /> (© 2025 International Federation of Gynecology and Obstetrics.) |
|---|---|
| ISSN: | 1879-3479 |
| DOI: | 10.1002/ijgo.70147 |